secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001104659-24-118284
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix Q3 net loss $36.5M; SOL-1 topline data expected Q4 2025
--------------------------------------------------------------------------

- Net loss of $36.5M ($0.22 diluted EPS) vs $0.5M loss in Q3 2023; R&D spend jumped to $37.1M.
- Total net revenue $15.4M (+2.3% YoY); DEXTENZA full-year 2024 revenue guided $62-67M.
- Cash $427.2M as of Sep 30, 2024, expected to fund operations into 2028.
- SOL-1 fully randomized by YE 2024 (accelerated); topline data now expected Q4 2025.
- SOL-R trial open for direct enrollment after FDA Type C response; NDA support confirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924118284/0001104659-24-118284-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924118284/tm2428320d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-118284

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer